We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Early-Detection Urine Test Is Effective for Lyme Disease

By LabMedica International staff writers
Posted on 01 Jun 2016
Prompt antibiotic treatment of early stage Lyme Borreliosis (LB) prevents progression to severe multisystem disease and there is a clinical need to improve the diagnostic specificity of early stage Lyme assays in the period prior to the mounting of a robust serology response.

The clinical presentation of LB can be so varied; early stage disease can be misdiagnosed for a variety of reasons including failure to develop an erythema migrans (EM) rash, failure of the patient or clinician to recognize an EM rash, if present, the non-specific nature of early symptoms and a negative or ambiguous serology.

Scientists at the George Mason University (Fairfax, VA, USA) obtained mid-stream urine specimens that were self-collected by 268 participants with all stages of documented or suspected Lyme disease. More...
Whole blood from each subject was drawn on the same day as urine collection. Blood samples were sent to Quest Diagnostics (Madison, NJ, USA) for Total Lyme Disease Antibody (EIA) and Lyme immunoglobulin G (IgG) and IgM Western Blot tests.

The scientists employed Nanotrap particles (Ceres Nanosciences, Manassas, VA, USA) to concentrate urinary OspA and used a highly specific anti-OspA monoclonal antibody (mAb) as a detector of the C-terminus peptides. They mapped the mAb epitope to a narrow specific OspA C-terminal domain OspA236-239 conserved across infectious Borrelia species but with no homology to human proteins and no cross-reactivity with relevant viral and non-Borrelia bacterial proteins. They collected 268 urine samples from patients being evaluated for all categories of LB in a LB endemic area. The urinary OspA assay, blinded to outcome, utilized Nanotrap particle pre-processing, western blotting to evaluate the OspA molecular size, and OspA peptide competition for confirmation.

The team found that in pre-treatment, 24/24 newly diagnosed patients with an erythema migrans (EM) rash were positive for urinary OspA while false positives for asymptomatic patients were 0/117. For 10 patients who exhibited persistence of the EM rash during the course of antibiotic therapy, 10/10 were positive for urinary OspA. Urinary OspA of 8/8 patients switched from detectable to undetectable following symptom resolution post-treatment. Specificity of the urinary OspA test for the clinical symptoms was 40/40. Specificity of the urinary OspA antigen test for later serology outcome was 87.5 % (21 urinary OspA positive/24 serology positive, and 41 of 100 patients under surveillance for persistent LB in an endemic area were positive for urinary OspA protein.

Alessandra Luchini, PhD, a professor and lead investigator of the study, said, “We're looking to repeat the story again with these other diseases. Other targets for the new type of test include Chagas disease, which is infectious and caused by a parasite, and toxoplasmosis, another parasite-borne disease.” The study was published originally published online on November 4, 2015, in the Journal of Translational Medicine.

Related Links:
George Mason University
Quest Diagnostics
Ceres Nanosciences

Gold Member
Respiratory Syncytial Virus Test
OSOM® RSV Test
Portable Electronic Pipette
Mini 96
Rapid Molecular Testing Device
FlashDetect Flash10
Sample Transportation System
Tempus1800 Necto
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New evidence shows viscoelastic testing can improve assessment of blood clotting during postpartum hemorrhage (Photo courtesy of 123RF)

Viscoelastic Testing Could Improve Treatment of Maternal Hemorrhage

Postpartum hemorrhage, severe bleeding after childbirth, remains one of the leading causes of maternal mortality worldwide, yet many of these deaths are preventable. Standard care can be hindered by delays... Read more

Immunology

view channel
Image: When assessing the same lung biopsy sample, research shows that only 18% of pathologists will agree on a TCMR diagnosis (Photo courtesy of Thermo Fisher)

Molecular Microscope Diagnostic System Assesses Lung Transplant Rejection

Lung transplant recipients face a significant risk of rejection and often require routine biopsies to monitor graft health, yet assessing the same biopsy sample can be highly inconsistent among pathologists.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.